BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18793387)

  • 1. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients.
    Fehm T; Krawczyk N; Solomayer EF; Becker-Pergola G; Dürr-Störzer S; Neubauer H; Seeger H; Staebler A; Wallwiener D; Becker S
    Breast Cancer Res; 2008; 10(5):R76. PubMed ID: 18793387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.
    Fehm T; Hoffmann O; Aktas B; Becker S; Solomayer EF; Wallwiener D; Kimmig R; Kasimir-Bauer S
    Breast Cancer Res; 2009; 11(4):R59. PubMed ID: 19664291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study.
    Synnestvedt M; Borgen E; Wist E; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Schirmer C; Nesland JM; Naume B
    BMC Cancer; 2012 Dec; 12():616. PubMed ID: 23259667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
    Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D
    Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the way to specifically targeting minimal residual disease?
    Gebauer G
    Breast Cancer Res; 2008; 10(5):112. PubMed ID: 18947365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study.
    Falck AK; Bendahl PO; Ingvar C; Isola J; Jönsson PE; Lindblom P; Lövgren K; Rennstam K; Fernö M; Rydén L
    BMC Cancer; 2012 Sep; 12():403. PubMed ID: 22963449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.
    Naume B; Synnestvedt M; Falk RS; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Sommer HH; Sætersdal AB; Rypdal MC; Bendigtsen Schirmer C; Wist EA; Borgen E
    J Clin Oncol; 2014 Dec; 32(34):3848-57. PubMed ID: 25366688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
    Krishnamurthy S; Cristofanilli M; Singh B; Reuben J; Gao H; Cohen EN; Andreopoulou E; Hall CS; Lodhi A; Jackson S; Lucci A
    Cancer; 2010 Jul; 116(14):3330-7. PubMed ID: 20564098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up.
    Hoffmann O; Schroer-Zuendorf IA; Kasimir-Bauer S; Oberhoff C; Kimmig R; Heubner M
    Arch Gynecol Obstet; 2015 Nov; 292(5):1117-25. PubMed ID: 25986892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis.
    Hartkopf AD; Brucker SY; Taran FA; Harbeck N; von Au A; Naume B; Pierga JY; Hoffmann O; Beckmann MW; Rydén L; Fehm T; Aft R; Solà M; Walter V; Rack B; Schuetz F; Borgen E; Ta MH; Bittner AK; Fasching PA; Fernö M; Krawczyk N; Weilbaecher K; Margelí M; Hahn M; Jueckstock J; Domschke C; Bidard FC; Kasimir-Bauer S; Schoenfisch B; Kurt AG; Wallwiener M; Gebauer G; Klein CA; Wallwiener D; Janni W; Pantel K
    Eur J Cancer; 2021 Sep; 154():128-137. PubMed ID: 34265505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
    Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
    Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients.
    Solomayer EF; Becker S; Pergola-Becker G; Bachmann R; Krämer B; Vogel U; Neubauer H; Wallwiener D; Huober J; Fehm TN
    Breast Cancer Res Treat; 2006 Jul; 98(2):179-84. PubMed ID: 16552629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of CTC and DTC-BM Detection for Adjuvant Therapy Effects and Prognosis Prediction in Early Breast Carcinoma: Results of 8-11 Years of Follow-up Evaluation.
    Takeyama H; Shimada T; Kinoshita S; Uchida K
    Ann Surg Oncol; 2017 May; 24(5):1227-1233. PubMed ID: 27909824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
    Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH
    Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study.
    Hoffmann O; Aktas B; Goldnau C; Heubner M; Oberhoff C; Kimmig R; Kasimir-Bauer S
    Anticancer Res; 2011 Oct; 31(10):3623-8. PubMed ID: 21965788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer.
    Daskalaki A; Agelaki S; Perraki M; Apostolaki S; Xenidis N; Stathopoulos E; Kontopodis E; Hatzidaki D; Mavroudis D; Georgoulias V
    Br J Cancer; 2009 Aug; 101(4):589-97. PubMed ID: 19623181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen-Friedenreich tumor antigen.
    Schindlbeck C; Jeschke U; Schulze S; Karsten U; Janni W; Rack B; Sommer H; Friese K
    Histochem Cell Biol; 2005 Jun; 123(6):631-7. PubMed ID: 15889266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy.
    Hartkopf AD; Taran FA; Wallwiener M; Hagenbeck C; Melcher C; Krawczyk N; Hahn M; Wallwiener D; Fehm T
    Breast Cancer Res; 2013; 15(5):R94. PubMed ID: 24099325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.
    Rexhepaj E; Brennan DJ; Holloway P; Kay EW; McCann AH; Landberg G; Duffy MJ; Jirstrom K; Gallagher WM
    Breast Cancer Res; 2008; 10(5):R89. PubMed ID: 18947395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.